# Insulet share price today (Insulet Corporation, PODD)

> Insulet Corporation's share price has fallen more than its earnings. Earnings per share fell 39.9% in a year while the price moved −50.5%. PODD · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/podd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: $154.86 (−50.5% in a year)
- P/E: 29.2× (lower than 94% of the last 4.6 years)
- Revenue (Jun 2026): $802 M (+23.5% on a year ago)
- Profit (Jun 2026): $95.0 M (+322.2% on a year ago)
- Operating margin: 16.2% (−2.5 points on a year ago)
- ROE: 16%, FY25
- ROIC: 20.9%, against a 9.8% cost of capital: +11.1 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Insulet share price today? Insulet Corporation's share price was $154.86 at the close on 3 November 2026. It has been falling for 29 weeks. That is 12.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $132 and $333, and at that close it sat 12% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 10 years the share price moved +382% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Insulet pay? Insulet Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Insulet on? Insulet is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Insulet profitable? Insulet Corporation earned $95.0 M of net profit in the Jun 2026 quarter, +322.2% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY25 profit was $247 M. Over 4 years profit has grown 95.8% a year on average. That is 11.8% of the quarter's revenue. The same quarter a year earlier earned $22.5 M. For the full year, FY25 profit was $247 M (−40.9% on the year before). Why profit moved: revenue changed +23.5% on a year earlier and the margin moved −2.5 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +123.3% and revenue +29.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Insulet make, and is it growing? Insulet Corporation reported $802 M of revenue in the Jun 2026 quarter, +23.5% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 25.3% a year on average. The last full year, FY25, came in at $2.7 B. The last four reported quarters add to $3.1 B. FY25 revenue was $2.7 B, +30.7% on the year before. Recent pace: the last four quarters grew +29.6% on average, against 25.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +29.4%, against +27.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +59.0%, against −2.6% a year (accelerating). ## How much of every $100 of sales does Insulet keep? Insulet Corporation's operating margin was 16.2% in the Jun 2026 quarter, 2.5 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 4.4% and 17.5%. The latest quarter is within that range. Across 5 years it has been between 4.4% and 17.5%, and FY25's 17.5% is the highest of them. Why the margin moved: operating margin changed −2.5 percentage points on the year while gross margin changed +0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Insulet's profit turning into cash? Over the last 3 years, 131% of Insulet Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $569 M of operating cash against $247 M of profit. After $192 M of spending on assets, $378 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Insulet's cash go? Insulet Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $392 M on assets over the last 3 years. Averaged over those years that is 4.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $392 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Insulet's P/E ratio, and how does it compare with its own history? Insulet Corporation's P/E is 29.2×, near the low end of its own history: it has been lower only 6% of the time. Its usual P/E (the middle reading) is 77.6×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved −39.9% while the price moved −50.5%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −1.6% a year; about +46.2% a year came from earnings growth and about −47.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Insulet business getting better or worse? Insulet Corporation's business is turning around. Profit growth has swung from −40.9% at its low to +59.0%, improving for 2 quarters in a row, with ROCE rising at 21.1%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Insulet earn on its capital? Insulet Corporation earned a ROE of 16% in FY25. That is up from a low of 1% in FY22. Its return on capital used (ROIC) is 11.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 9.1% net margin and 0.85× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 9.1% net margin × 0.85× asset turnover × 2.11× leverage (assets divided by equity) ≈ 16.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 20.9% − 9.8% = +11.1 percentage points. The 9.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 20.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 19.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Insulet have too much debt? Insulet Corporation has total debt of $948 M against shareholder equity of $1.4 B as of Jun 2026, so its debt is 0.67× its equity. Year by year, that ratio went from 2.31 in FY21 to 0.66 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Insulet shareholding pattern? 8.2% of Insulet Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Insulet from balance-sheet trouble? For Insulet Corporation, the Z-score is 8.46. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 8.46 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Insulet rank in its industry? 58.5 out of 100, rank 5 of 30 in Medical Devices, with 71% of the evidence available. Insulet Corporation scores 58.5 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 5. Earnings are strong; relative strength in its sector is -31% and the one-year return is -51.6%. The four parts add up to the total exactly: 23.8 + 18.9 + 9.3 + 6.5 = 58.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Insulet compared with? Insulet ranks 5 of 30 Medical Devices companies on the 4-Factor Sector Score, with 58.5 out of 100. 1. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) DXCM · losing its lead · Most evidence points up · 81% evidence 74.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 15.5% · Profit 74.8% · Operating margin change 5.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 27.8% · Operating margin 24.3% · 76% evidence Valuation 13.6/20 · P/E 26× · PEG 0.66 · 65% evidence Relative strength 11.6/20 · Lead over its industry 2.6% · Lead over S&P 500 8.7% · 1 year 50.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28 + 20.9 + 13.6 + 11.6 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) GMED · basing · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 19.8% · Profit 50.1% · Operating margin change 7.5 points · 83% evidence Capital efficiency 17.5/25 · ROCE 14.6% · Operating margin 24.8% · 76% evidence Valuation 14.9/20 · P/E 20× · PEG 0.4 · 65% evidence Relative strength 3.3/20 · Lead over its industry -15.4% · Lead over S&P 500 -10.3% · 1 year -5.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28 + 17.5 + 14.9 + 3.3 = 63.7 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -5.1%. 3. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) BSX · quiet · Evidence leans up · 81% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 13.5% · Profit 46.7% · Operating margin change 4.3 points · 83% evidence Capital efficiency 16.3/25 · ROCE 11.4% · Operating margin 22.9% · 76% evidence Valuation 15.6/20 · P/E 17.3× · PEG 0.37 · 65% evidence Relative strength 4.8/20 · Lead over its industry -38.8% · Lead over S&P 500 -35.7% · 1 year -56.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 16.3 + 15.6 + 4.8 = 61.7 · What this means: Earnings are strong; relative strength in its sector is -38.8% and the one-year return is -56.5%. 4. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) HAE · leader · Evidence leans up · 81% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0.3% · Profit -40.5% · Operating margin change 0 points · 83% evidence Capital efficiency 15.3/25 · ROCE 11.8% · Operating margin 17.9% · 76% evidence Valuation 13.3/20 · P/E 36.5× · PEG 0.49 · 65% evidence Relative strength 19.7/20 · Lead over its industry 36.9% · Lead over S&P 500 44.6% · 1 year 76% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.8 + 15.3 + 13.3 + 19.7 = 59.1 · What this means: Relative strength against the index is 44.6%, and revenue and profit growth are weak. 5. Insulet Corporation this page PODD · turning · Evidence leans up · 71% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 29.4% · Profit 58.6% · Operating margin change -2.5 points · 83% evidence Capital efficiency 18.9/25 · ROCE 21.3% · Operating margin 16.2% · 76% evidence Valuation 9.3/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -31% · Lead over S&P 500 -27.5% · 1 year -51.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.8 + 18.9 + 9.3 + 6.5 = 58.5 · What this means: Earnings are strong; relative strength in its sector is -31% and the one-year return is -51.6%. 6. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) SYK · basing · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 8.5% · Profit 27.8% · Operating margin change 5 points · 83% evidence Capital efficiency 18.8/25 · ROCE 14.9% · Operating margin 27% · 76% evidence Valuation 11.0/20 · P/E 32.4× · PEG 1.16 · 65% evidence Relative strength 4.8/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.7% · 1 year -12.8% · 100% evidence · 1 of 12 weeks ahead Exact sum: 22.6 + 18.8 + 11 + 4.8 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) GKOS · leader · Evidence leans up · 64% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.2/35 · Revenue 41.8% · Profit n/a · Operating margin change 9.8 points · 62% evidence Capital efficiency 3.9/25 · ROCE -9.7% · Operating margin -8.5% · 76% evidence Valuation 11.2/20 · P/E -98.1× · PEG n/a · 15% evidence Relative strength 19.7/20 · Lead over its industry 53.6% · Lead over S&P 500 62.8% · 1 year 177.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.2 + 3.9 + 11.2 + 19.7 = 57 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Medtronic plc](https://www.sectoralpha.in/us/stocks/mdt) MDT · breaking out · Evidence leans up · 85% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 9.8% · Profit 12.3% · Operating margin change 0.6 points · 95% evidence Capital efficiency 14.3/25 · ROCE 9.4% · Operating margin 19.3% · 76% evidence Valuation 9.3/20 · P/E 20.9× · PEG 1.72 · 65% evidence Relative strength 12.8/20 · Lead over its industry -1.7% · Lead over S&P 500 3.9% · 1 year 7.2% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.1 + 14.3 + 9.3 + 12.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) STE · basing · Evidence leans up · 81% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 8.3% · Profit 24.7% · Operating margin change 1.4 points · 83% evidence Capital efficiency 15.4/25 · ROCE 12.2% · Operating margin 19.2% · 76% evidence Valuation 12.5/20 · P/E 25.5× · PEG 1 · 65% evidence Relative strength 7.3/20 · Lead over its industry -10.1% · Lead over S&P 500 -4.9% · 1 year -12.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.7 + 15.4 + 12.5 + 7.3 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) EW · turning · Evidence leans up · 81% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 14.6% · Profit -75.8% · Operating margin change 1.7 points · 83% evidence Capital efficiency 18.6/25 · ROCE 14.8% · Operating margin 29.8% · 76% evidence Valuation 3.9/20 · P/E 51.8× · PEG 5.03 · 65% evidence Relative strength 13.2/20 · Lead over its industry 0.1% · Lead over S&P 500 6.2% · 1 year 14.2% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.1 + 18.6 + 3.9 + 13.2 = 53.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [Koninklijke Philips N.V.](https://www.sectoralpha.in/us/stocks/phg) PHG · turning · Evidence leans up · 71% evidence 52.3 out of 100 Growth Capital Valuation Relative
12. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) CNMD · quiet · Evidence leans up · 81% evidence 52.2 out of 100 Growth Capital Valuation Relative
13. [Integer Holdings Corporation](https://www.sectoralpha.in/us/stocks/itgr) ITGR · losing its lead · Too little evidence to rank firmly · 56% evidence 50.8 out of 100 Growth Capital Valuation Relative
14. [iRhythm Holdings, Inc.](https://www.sectoralpha.in/us/stocks/irtc) IRTC · turning · Evidence leans down · 64% evidence 49.4 out of 100 Growth Capital Valuation Relative
15. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) BFLY · quiet · Evidence leans down · 61% evidence 48.9 out of 100 Growth Capital Valuation Relative
16. [UFP Technologies, Inc.](https://www.sectoralpha.in/us/stocks/ufpt) UFPT · losing its lead · Evidence leans down · 81% evidence 48.3 out of 100 Growth Capital Valuation Relative
17. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) SNN · turning · Too little evidence to rank firmly · 51% evidence 48.1 out of 100 Growth Capital Valuation Relative
18. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) LIVN · turning · Evidence leans down · 64% evidence 47.6 out of 100 Growth Capital Valuation Relative
19. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) GEHC · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
20. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) ZBH · turning · Evidence leans down · 81% evidence 45.9 out of 100 Growth Capital Valuation Relative
21. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) BRKR · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
22. [Neogen Corporation](https://www.sectoralpha.in/us/stocks/neog) NEOG · turning · Evidence leans down · 67% evidence 44.8 out of 100 Growth Capital Valuation Relative
23. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) BIO · leader · Evidence leans down · 71% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Axogen, Inc.](https://www.sectoralpha.in/us/stocks/axgn) AXGN · turning · Evidence leans down · 64% evidence 42.1 out of 100 Growth Capital Valuation Relative
25. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) ESTA · basing · Evidence leans down · 61% evidence 40.7 out of 100 Growth Capital Valuation Relative
26. [Inspire Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/insp) INSP · breaking out · Evidence leans down · 74% evidence 39.4 out of 100 Growth Capital Valuation Relative
27. [NovoCure Limited](https://www.sectoralpha.in/us/stocks/nvcr) NVCR · quiet · Evidence leans down · 61% evidence 37.8 out of 100 Growth Capital Valuation Relative
28. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) PEN · turning · Evidence leans down · 81% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [TransMedics Group, Inc.](https://www.sectoralpha.in/us/stocks/tmdx) TMDX · quiet · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
30. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) ABT · turning · Most evidence points down · 85% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Devices](https://www.sectoralpha.in/us/sectors/medical-devices), all 30 compared on one page. ## Which companies are close to Insulet in size? Insulet is the 14th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Glaukos Corporation, Penumbra, Inc. and Smith & Nephew plc. Just below it: Globus Medical, Inc., Bio-Rad Laboratories, Inc. and Bruker Corporation. ### Medical Devices companies close in size

1. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) $13.8 billion
2. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) $12.6 billion
3. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) $12.5 billion
4. Insulet Corporation $10.7 billion
5. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) $10.7 billion
6. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) $10 billion
7. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) $8.6 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Albemarle Corporation](https://www.sectoralpha.in/us/stocks/alb) $10.7 billion · Specialty Chemicals
2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) $10.7 billion · Medical Devices
3. Insulet Corporation $10.7 billion
4. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) $10.6 billion · Medical Care Facilities
5. [The AES Corporation](https://www.sectoralpha.in/us/stocks/aes) $10.6 billion · Utilities - Diversified

## What else do people ask about Insulet? ### What were Insulet's latest quarterly results? Insulet Corporation reported revenue of $802 M and net profit of $95.0 M for the Jun 2026 quarter. Revenue rose 23.5% and profit rose 322.2% compared with a year earlier. Earnings per share were $1.37. The operating margin was 16.2%, 2.5 percentage points lower than a year earlier (as of 3 November 2026). ### What is Insulet's market cap? Insulet Corporation's market capitalisation is $10.7 B at a stock price of $154.86. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Insulet performing? Insulet Corporation's share price has been falling for 29 weeks. In its latest quarter, revenue rose 23.5% and profit rose 322.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 1 week running (as of 3 November 2026). ### Will Insulet's stock price go up? This page does not forecast Insulet Corporation's stock price. What it shows instead: the stock price is $154.86, and it has been falling for 29 weeks. Its P/E of 29.2× is higher than 6% of its own last 5 years (as of 3 November 2026). ### Does Insulet have too much debt? Insulet Corporation has a moderate amount of debt: its debt is 0.71× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Insulet in its business cycle? Insulet Corporation's FY25 operating margin was 17.5%, against a 5-year range of 4.4% to 17.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 16.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Insulet story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Insulet a stock worth studying right now? What the numbers show: Insulet Corporation's share price has fallen more than its earnings. Earnings per share fell 39.9% in a year while the price moved −50.5%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.